Compare
Up to four compounds, side by side.
Useful for choosing between similar peptides or planning a stack.
Add a peptide
| Attribute | Myostatin Inhibitor ACE-031 |
|---|---|
| Summary | Clinical-grade myostatin pathway inhibitor — terminated in muscle dystrophy trials. |
| Mechanism | Soluble activin receptor type IIB decoy — sponges up myostatin. |
| Top outcomes |
|
| Evidence | emerging |
| Half-life | ~10-15 days |
| Administration | subq |
| Legal status | research only |
| Safety | Vascular side effects (nosebleeds, gum bleeding) led to trial halts. |